Premium
Week 96 results of the randomized, multicentre Maraviroc Switch ( MARCH ) study
Author(s) -
Pett SL,
Amin J,
Horban A,
AndradeVillanueva J,
Losso M,
Porteiro N,
Madero JS,
Belloso W,
Tu E,
Silk D,
Kelleher A,
Harrigan R,
Clark A,
Sugiura W,
Wolff M,
Gill J,
Gatell J,
Clarke A,
Ruxrungtham K,
Prazuck T,
Kaiser R,
Woolley I,
Alberto Arnaiz J,
Cooper D,
Rockstroh JK,
Mallon P,
Emery S
Publication year - 2018
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12532
Subject(s) - maraviroc , medicine , regimen , randomization , randomized controlled trial , clinical endpoint , confidence interval , viral load , ritonavir , ccr5 receptor antagonist , population , intention to treat analysis , gastroenterology , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , chemokine , receptor , chemokine receptor , environmental health
Objectives The Maraviroc Switch ( MARCH ) study week 48 data demonstrated that maraviroc, a chemokine receptor‐5 (CCR5) inhibitor, was a safe and effective switch for the ritonavir‐boosted protease inhibitor ( PI /r) component of a two nucleos(t)ide reverse transcriptase inhibitor [N(t) RTI ] plus PI /r‐based antiretroviral regimen in patients with R5‐tropic virus. Here we report the durability of this finding. Methods MARCH , an international, multicentre, randomized, 96‐week open‐label switch study, enrolled HIV ‐1‐infected adults with R5‐tropic virus who were stable (> 24 weeks) and virologically suppressed [plasma viral load ( pVL ) < 50 HIV ‐1 RNA copies/ mL ]. Participants were randomized to continue their current PI /r‐based regimen ( PI /r) or to switch to MVC plus two N(t) RTI s ( MVC ) (1:2 randomization). The primary endpoint was the difference in the proportion with pVL < 200 copies/ mL at 96 weeks. The switch arm was defined as noninferior if the lower limit of the 95% confidence interval ( CI ) for the difference was < −12% in the intention‐to‐treat ( ITT ) population. Safety endpoints (the difference in the mean change from baseline or a comparison of proportions) were analysed as key secondary endpoints. Results Eighty‐two ( PI /r) and 156 ( MVC ) participants were randomized and included in the ITT analysis; 71 (87%) and 130 (83%) were in follow‐up and on therapy at week 96. At week 96, 89.0% and 90.4% in the PI /r and MVC arms, respectively, had pVL < 50 copies/ mL (95% CI ‐6.6, 10.2). Moreover, in those switching away from PI /r, there were significant reductions in mean total cholesterol (differences 0.31 mmol/L; P = 0.02) and triglycerides (difference 0.44 mmol/L; P < 0.001). Changes in CD 4 T‐cell count, renal function, and serious and nonserious adverse events were similar in the two arms. Conclusions MVC as a switch for a PI /r is safe and effective at maintaining virological suppression while having significant lipid benefits over 96 weeks.